Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1Phase 1 1

Status

Completed 2Unknown 1

Sponsor Class

NIH 3OTHER 2

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 9Other hematologic neoplasm 6Dermatologic 4Thoracic 3Gastrointestinal 2Sarcoma 1Plasma cell 1Other solid neoplasm 1Myeloid 1Genitourinary 1Breast 1

Conditions

Small Cell Lung Carcinoma 1Lung Neoplasms 1Extensive Stage Small Cell Lung Cancer 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 71Carboplatin 68Paclitaxel 57Radiotherapy 43Specimen Handling 37Gemcitabine 36Erlotinib Hydrochloride 32Etoposide 30Magnetic Resonance Spectroscopy 29Docetaxel 28Taxes 27Pemetrexed 23Platinum 20Vinorelbine 191,2-diaminocyclohexaneplatinum II citrate 19Bevacizumab 18Cyclophosphamide 16Biopsy 16Radiation 15pembrolizumab 14Immunoglobulin G 12Disulfides 12Topotecan 11Gefitinib 11durvalumab 9atezolizumab 9aldesleukin 9Nivolumab 9Irinotecan 9Bortezomib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × oblimersen × Thoracic × Clear all
NCT00030641 2014-01-06

Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2/3 Unknown
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00017251 2013-01-24

Combination Chemotherapy Plus Oblimersen in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1 Completed
12 enrolled
Thoracic

Extensive Stage Small Cell Lung Cancer

NCT00042978 2013-01-14

Carboplatin and Etoposide With or Without Oblimersen Sodium in Treating Patients With Extensive Stage Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Completed
55 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡